



Tackling CDKL5 Deficiency

How can a non-profit advance research into a specific rare disease?


Majid Jafar
Co-Founder, Loulou Foundation

ECRD 2018
12 May 2018

“Just one letter”



CDKL5 deficiency disorder



- Rare, X-linked disorder defined by spontaneous loss-of-function mutations in one copy of the **CDKL5 gene**.
- **Incidence 1 in 40-50,000.** One of the most common causes of genetic epilepsy.
- **Intractable infantile seizures** within the first months after birth.
- Severe **developmental delay** leading to intellectual disability, along with speech, visual, and motor deficits.
- **No effective treatment available.** 1 Orphan Drug Designation.

The Loulou Foundation

- **Genesis and Strategy** – De-risking CDKL5 Deficiency Disorder
- **Multiple Approaches** – Treatments and Cures
- **Parallel Objectives:**
 - Funding Academic Research
 - Engaging and Enabling Industry
 - Breaking Down Barriers
 - Plugging the Gaps – Translational Toolkit/ Regulatory

The Loulou Foundation




ABOUT US CDKL5 ANNOUNCEMENTS GRANTS & AWARDS TEAM TRUSTEES CONTACT

ADVANCING RESEARCH INTO THE UNDERSTANDING AND
DEVELOPMENT OF THERAPEUTICS FOR CDKL5 DEFICIENCY
DISORDER



<http://www.louloufoundation.org/>

The Loulou Foundation



<http://www.louloufoundation.org/>

